Article | Published:

Suppression of MIF-induced neuronal apoptosis may underlie the therapeutic effects of effective components of Fufang Danshen in the treatment of Alzheimer's disease

Acta Pharmacologica Sinicavolume 39pages14211438 (2018) | Download Citation



Fufang Danshen (FFDS or Compound Danshen) consists of three Chinese herbs Danshen (Salviae miltiorrhizae radix et rhizome), Sanqi (Notoginseng radix et rhizome) and Tianranbingpian (Borneolum, or D-borneol), which has been show to significantly improve the function of the nervous system and brain metabolism. In this study we explored the possible mechanisms underlying the therapeutic effects of the combination of the effective components of FFDS (Tan IIA, NG-R1 and Borneol) in the treatment of Alzheimer's disease (AD) based on network pharmacology. We firstly constructed AD-related FFDS component protein interaction networks, and revealed that macrophage migration inhibitory factor (MIF) might regulate neuronal apoptosis through Bad in the progression of AD. Then we investigated the apoptosis-inducing effects of MIF and the impact of the effective components of FFDS in human neuroblastoma SH-SY5Y cells. We observed the characteristics of a “Pendular state” of MIF, where MIF (8 ng/mL) increased the ratio of p-Bad/Bad by activating Akt and the IKKα/β signaling pathway to assure cell survival, whereas MIF (50 ng/mL) up-regulated the expression of Bad to trigger apoptosis of SH-SY5Y cells. MIF displayed neurotoxicity similar to Aβ1-42, which was associated with the MIF-induced increased expression of Bad. Application of the FFDS composite solution significantly decreased the expression levels of Bad, suppressed MIF-induced apoptosis in SH-SY5Y cells. In a D-galactose- and AlCl3-induced AD mouse model, administration of the FFDS composite solution significantly improved the learning and memory, as well as neuronal morphology, and decreased the serum levels of INF-γ. Therefore, the FFDS composite solution exerts neuroprotective effects through down-regulating the level of Bad stimulated by MIF.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. 1

    Fang J, Wang L, Wu T, Yang C, Gao L, Cai H, et al. Network pharmacology-based study on the mechanism of action for herbal medicines in Alzheimer treatment. J Ethnopharmacol 2017; 196: 281–92.

  2. 2

    De-Paula VJ, Radanovic M, Diniz BS, Forlenza OV. Alzheimer's disease. Subcell Biochem 2012; 65: 329–52 .

  3. 3

    Marks N, Berg MJ. BACE and gamma-secretase characterization and their sorting as therapeutic targets to reduce amyloidogenesis. Neurochem Res 2010; 35: 181–210.

  4. 4

    Gervais FG, Xu D, Robertson GS, Vaillancourt JP, Zhu Y, Huang J, et al. Involvement of caspases in proteolytic cleavage of Alzheimer's amyloid-beta precursor protein and amyloidogenic A beta peptide formation. Cell 1999; 97: 395–406.

  5. 5

    Yuan J, Yankner BA. Apoptosis in the nervous system. Nature 2000; 407: 802–9.

  6. 6

    Yang J, Li JH, Wang J, Zhang CY. Molecular modeling of BAD complex resided in a mitochondrion integrating glycolysis and apoptosis. J Theor Biol 2010; 266: 231–41.

  7. 7

    Chong ZZ, Maiese K. Targeting WNT, protein kinase B, and mitochondrial membrane integrity to foster cellular survival in the nervous system. Histol Histopathol 2004; 19: 495–504.

  8. 8

    Castellani RJ, Rolston RK, Smith MA. Alzheimer disease. Dis Mon 2010; 56: 484–546.

  9. 9

    Zhang Y, Pi Z, Song F, Liu Z. Ginsenosides attenuate d-galactose- and AlCl3-inducedspatial memory impairment by restoring the dysfunction of the neurotransmitter systems in the rat model of Alzheimer's disease. J Ethnopharmacol 2016; 194: 188–95.

  10. 10

    Liu M, Guo H, Li C, Wang D, Wu J, Wang C, et al. Cognitive improvement of compound danshen in an Aβ25-35 peptide-induced rat model of Alzheimer's disease. BMC Complement Altern Med 2015; 15: 382.

  11. 11

    Ma B, Meng X, Wang J, Sun J, Ren X, Qin M, et al. Notoginsenoside R1 attenuates amyloid-β-induced damage in neurons by inhibiting reactive oxygen species and modulating MAPK activation. Int Immunopharmacol 2014; 22: 151–9.

  12. 12

    Cui ZT, Liu JP, Wei WL. The effects of tanshinone IIA on hypoxia/reoxygenation-induced myocardial microvascular endothelial cell apoptosis in rats via the JAK2/STAT3 signaling pathway. Biomed Pharmacother 2016; 83: 1116–26.

  13. 13

    Jiang P, Li C, Xiang Z, Jiao B. Tanshinone IIA reduces the risk of Alzheimer's disease by inhibiting iNOS, MMP-2 and NF-κB p65 transcription and translation in the temporal lobes of rat models of Alzheimer's disease. Mol Med Rep 2014; 10: 689–94.

  14. 14

    Hur J, Pak SC, Koo BS, Jeon S. Borneol alleviates oxidative stress via upregulation of Nrf2 and Bcl-2 in SH-SY5Y cells. Pharm Biol 2013; 51: 30–5.

  15. 15

    Zhang Q, Wu D, Wu J, Ou Y, Mu C, Han B, et al. Improved blood-brain barrier distribution: effect of borneol on the brain pharmacokinetics of kaempferol in rats by in vivo microdialysis sampling. J Ethnopharmacol 2015; 162: 270–7.

  16. 16

    Han M, Liu Y, Zhang B, Qiao J, Lu W, Zhu Y, et al. Salvianic borneol ester reduces β-amyloid oligomers and prevents cytotoxicity. Pharm Biol 2011; 49: 1008–13.

  17. 17

    Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, et al. Inflammation and Alzheimer's disease. Neurobiol Aging 2000; 21: 383–421.

  18. 18

    Wu D, Zhang X, Zhao M, Zhou AL. The role of the TLR4/NF-κB signaling pathway in Aβ accumulation in primary hippocampal neurons. Acta Physiol Sin 2015; 67: 319–28.

  19. 19

    Wang F, Shen X, Guo X, Peng Y, Liu Y, Xu S, et al. Spinal macrophage migration inhibitory factor contributes to the pathogenesis of inflammatory hyperalgesia in rats. Pain 2010; 148: 275–83.

  20. 20

    Wang F, Xu S, Shen X, Guo X, Peng Y, Yang J. Spinal macrophage migration inhibitory factor is a major contributor to rodent neuropathic pain-like hypersensitivity. Anesthesiology 2011; 114: 643–59.

  21. 21

    Bacher M, Deuster O, Aljabari B, Egensperger R, Neff F, Jessen F, et al. The role of macrophage migration inhibitory factor in Alzheimer's disease. Mol Med 2010; 16: 116–21.

  22. 22

    Qi Q, Li R, Li HY, Cao YB, Bai M, Fan XJ, et al. Identification of the anti-tumor activity and mechanisms of nuciferine through a network pharmacology approach. Acta Pharmacol Sin 2016; 37: 963–72.

  23. 23

    Zhao N, Li J, Li L, Niu XY, Jiang M, He XJ, et al. Molecular network-based analysis of guizhi-shaoyao-zhimu decoction, a TCM herbal formula, for treatment of diabetic peripheral neuropathy. Acta Pharmacol Sin 2015; 36: 716–23.

  24. 24

    Goh KI, Cusick ME, Valle D, Childs B, Vidal M, Barabási AL. The human disease network. Proc Natl Acad Sci U S A 2007; 104: 8685–90.

  25. 25

    Vázquez-Higuera JL, Mateo I, Sánchez-Juan P, Rodríguez-Rodríguez E, Pozueta A, Calero M, et al. Genetic variation in the tau kinases pathway may modify the risk and age at onset of Alzheimer's disease. J Alzheimers Dis 2011; 27: 291–7.

  26. 26

    Schnöder L, Mateo I, Sánchez-Juan P, Rodríguez-Rodríguez E, Pozueta A, Calero M, et al. Deficiency of neuronal p38α-MAPK attenuates amyloid pathology in Alzheimer's mouse and cell models through facilitating lysosomal degradation of BACE1. J Biol Chem 2016; 291: 2067–79.

  27. 27

    Wang D, Fu Q, Zhou Y, Xu B, Shi Q, Igwe B, et al. β2 adrenergic receptor, protein kinase A (PKA) and c-Jun N-terminal kinase (JNK) signaling pathways mediate tau pathology in Alzheimer disease models. J Biol Chem 2013; 288: 10298–307.

  28. 28

    Akhter R, Sanphui P, Das H, Saha P, Biswas SC. The regulation of p53 up-regulated modulator of apoptosis by JNK/c-Jun pathway in β-amyloid-induced neuron death. J Neurochem 2015; 134: 1091–103.

  29. 29

    Bamji-Mirza M, Callaghan D, Najem D, Shen S, Hasim MS, Yang Z, et al. Stimulation of insulin signaling and inhibition of JNK-AP1 activation protect cells from amyloid-β-induced signaling dysregulation and inflammatory response. J Alzheimers Dis 2014; 40: 105–22.

  30. 30

    Vukic V, Callaghan D, Walker D, Lue LF, Liu QY, Couraud PO, et al. Expression of inflammatory genes induced by beta-amyloid peptides in human brain endothelial cells and in Alzheimer's brain is mediated by the JNK-AP1 signaling pathway. Neurobiol Dis 2009; 34: 95–106.

  31. 31

    Giovannini MG, Cerbai F, Bellucci A, Melani C, Grossi C, Bartolozzi C, et al. Differential activation of mitogen-activated protein kinase signalling pathways in the hippocampus of CRND8 transgenic mouse, a model of Alzheimer's disease. Neurosci 2008; 153: 618–33.

  32. 32

    Ferrer I, Blanco R, Carmona M, Ribera R, Goutan E, Puig B, et al. Phosphorylated map kinase (ERK1, ERK2) expression is associated with early tau deposition in neurones and glial cells, but not with increased nuclear DNA vulnerability and cell death, in Alzheimer disease, Pick's disease, progressive supranuclear palsy and corticobasal degeneration. Brain Pathol 2001; 11: 144–58.

  33. 33

    Dineley KT, Westerman M, Bui D, Bell K, Ashe KH. Sweatt JD. Beta-amyloid activates the mitogen-activated protein kinase cascade via hippocampal alpha7 nicotinic acetylcholine receptors: In vitro and in vivo mechanisms related to Alzheimer's disease. J Neurosci 2001; 21: 4125–33.

  34. 34

    Shi C, Zhu X, Wang J, Long D. Intromitochondrial IκB/NF-κB signaling pathway is involved in amyloid β peptide-induced mitochondrial dysfunction. J Bioenerg Biomembr 2014; 46: 371–6.

  35. 35

    Tsuchiya Y, Asano T, Nakayama K. Kato T Jr, Karin M, Kamata H. Nuclear IKKbeta is an adaptor protein for IkappaBalpha ubiquitination and degradation in UV-induced NF-kappaB activation. Mol Cell 2010; 39: 570–82.

  36. 36

    Yan J, Xiang J, Lin Y, Ma J, Zhang J, Zhang H, et al. Inactivation of BAD by IKK inhibits TNFα-induced apoptosis independently of NF-κB activation. Cell 2013; 152: 304–15.

  37. 37

    Liu Y, Liu X, Hao W, Decker Y, Schomburg R, Fülöp L, et al. IKKβ deficiency in myeloid cells ameliorates Alzheimer's disease-related symptoms and pathology. J Neurosci 2014; 34: 12982–99.

  38. 38

    Capiralla H, Vingtdeux V, Zhao H, Sankowski R, Al-Abed Y, Davies P, et al. Resveratrol mitigates lipopolysaccharide- and Aβ-mediated microglial inflammation by inhibiting the TLR4/NF-κB/STAT signaling cascade. J Neurochem 2012; 120: 461–72.

  39. 39

    Geetha T, Chen Z, McGregor WC, Douglas White B, Diaz-Meco MT, Moscat J, et al. TRAF6 and p62 inhibit amyloid β-induced neuronal death through p75 neurotrophin receptor. Neurochem Int 2012; 61: 1289–93.

  40. 40

    Tien NT, Karaca I, Tamboli IY, Walter J. Trehalose alters subcellular trafficking and the metabolism of the Alzheimer-associated amyloid precursor protein. J Biol Chem 2016; 291: 10528–40.

  41. 41

    Poon WW, Carlos AJ, Aguilar BL, Berchtold NC, Kawano CK, Zograbyan V, et al. β-Amyloid (Aβ) oligomers impair brain-derived neurotrophic factor retrograde trafficking by down-regulating ubiquitin C-terminal hydrolase, UCH-L1. J Biol Chem 2013; 288: 16937–48.

  42. 42

    Corsetti V, Florenzano F, Atlante A, Bobba A, Ciotti MT, Natale F, et al. NH2-truncated human tau induces deregulated mitophagy in neurons by aberrant recruitment of Parkin and UCHL-1: implications in Alzheimer's disease. Hum Mol Genet 2015; 24: 3058–81.

  43. 43

    Guglielmotto M, Monteleone D, Boido M, Piras A, Giliberto L, Borghi R, et al. Aβ1-42-mediated down-regulation of Uch-L1 is dependent on NF-κB activation and impaired BACE1 lysosomal degradation. Aging Cell 2012; 11: 834–44.

  44. 44

    Wang Z, Xue Y, Wang P, Zhu J, Ma J. miR-608 inhibits the migration and invasion of glioma stem cells by targeting macrophage migration inhibitory factor. Oncol Rep 2016; 35: 2733–42.

  45. 45

    Dłużniewska J, Beręsewicz M. Transient cerebral ischemia induces delayed proapoptotic Bad translocation to mitochondria in CA1 sector of hippocampus. Mol Brain Res 2005; 133: 274–80.

  46. 46

    Fu Z, Yang J, Wei Y, Li J. Effects of piceatannol and pterostilbene against β-amyloid-induced apoptosis on the PI3K/Akt/Bad signaling pathway in PC12 cells. Food Funct 2016; 7: 1014–23.

  47. 47

    Niino M, Ogata A, Kikuchi S, Tashiro K, Nishihira J. Macrophage migration inhibitory factor in the cerebrospinal fluid of patients with conventional and optic-spinal forms of multiple sclerosis and neuro-Behçet's disease. J Neurol Sci 2000; 179: 127–31.

  48. 48

    Li Q, Fang J, Yang M, Wu D, Zhang L, Zhang Y. Galantamine inhibits calpain-calcineurin signaling activated by beta-amyloid in human neuroblastoma SH-SY5Y cells. Neurosci Lett 2010; 480: 173–7.

  49. 49

    Agostinho P, Lopes JP, Velez Z, Oliveira CR. Overactivation of calcineurin induced by amyloid-beta and prion proteins. Neurochem Int 2008; 52: 1226–33.

  50. 50

    Li SQ, Yu Y, Han JZ, Wang D, Liu J, Qian F, et al. Deficiency of macro-phage migration inhibitory factor attenuates tau hyperphosphorylation in mouse models of Alzheimer's disease. J Neuroinflammation 2015; 12: 177.

  51. 51

    Zhang J, Ding YR, Wang R. Inhibition of tissue transglutaminase promotes Aβ-induced apoptosis in SH-SY5Y cells. Acta Pharmacol Sin 2016; 37: 1534–42.

  52. 52

    Tan X, Li J, Wang X, Chen N, Cai B, Wang G, et al. Tanshinone IIA protects against cardiac hypertrophy via inhibiting calcineurin/NFATc3 pathway. Int J Biol Sci 2011; 7: 383–9.

  53. 53

    Peng XM, Gao L, Huo SX, Liu XM, Yan M. The mechanism of memory enhancement of acteoside (verbascoside) in the senescent mouse model induced by a combination of D-gal and AlCl3. Phytother Res 2015; 29: 1137–44.

  54. 54

    Yang W, Shi L, Chen L, Zhang B, Ma K, Liu Y, Qian Y. Protective effects of perindopril on d-galactose and aluminum trichloride induced neurotoxicity via the apoptosis of mitochondria-mediated intrinsic pathway in the hippocampus of mice. Brain Res Bull 2014; 109: 46–53.

Download references


This work was supported by a grant from the Specialized Research Fund for the Doctoral Program of Higher Education of China (20120091110038), the National Natural Science Foundation of China (J1103512 and J1210026), the Open Project of State Key Laboratory of Proteomics (SKLP-O201415), and the Open Project of State Key Laboratory of Pharmaceutical Biotechnology (KF-GN-201405).

Author information

Author notes

  1. These authors contributed equally to this work.


  1. State Key Laboratory of Pharmaceutical Biotechnology, College of Life Sciences, Nanjing University, Nanjing, 210093, China

    • Cheng-jie Liang
    • , Jia-huang Li
    • , Zhen Zhang
    • , Ju-yan Zhang
    •  & Jie Yang
  2. State Key Laboratory of Proteomics, Beijing Proteome Research Center, Beijing Institute of Radiation Medicine, Beijing, 100850, China

    • Cheng-jie Liang
    •  & Jie Yang
  3. Laboratory for Conservation and Utilization of Bio-resources, Yunnan University, Kunming, 650091, China

    • Shu-qun Liu


  1. Search for Cheng-jie Liang in:

  2. Search for Jia-huang Li in:

  3. Search for Zhen Zhang in:

  4. Search for Ju-yan Zhang in:

  5. Search for Shu-qun Liu in:

  6. Search for Jie Yang in:

Corresponding authors

Correspondence to Shu-qun Liu or Jie Yang.

About this article

Publication history